A phase 3 clinical trial has begun enrolling patients to assess a potential first-in-class oral therapy to treat patients with Type 1 diabetes that has the potential to improve glycemia and reduce the risk of hypoglycemia. Developed by vTV Therapeutics, cadisegliatin is being studied as an adjunct to the use of insulin in adults with Type 1 diabetes.

Type 1 diabetes is an autoimmune disease where the immune system destroys insulin-producing beta cells in pancreatic islets. About 2 million Americans have Type 1 diabetes. Hypoglycemia is a serious complication where glucose levels become too low. About 4% of patients using insulin experience hypoglycemia, but patients generally only seek treatment when symptoms are severe.

“Although there have been major advances in medical devices for

See Full Page